Status:

TERMINATED

Sorafenib-induced Hand- Foot Skin Reaction Treatment

Lead Sponsor:

Northwestern University

Collaborating Sponsors:

Bayer

Conditions:

Hand-foot Skin Reaction

Rash

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

The purpose of this study is to evaluate treatments for a rash caused by sorafenib.

Detailed Description

This study will compare compare the effectiveness of four creams (urea 40% cream, fluocinonide 0.05% cream, tazarotene 0.1% cream, and Udderly smooth® Udder Cream) in treating hand-foot skin reaction ...

Eligibility Criteria

Inclusion

  • Patients receiving sorafenib as monotherapy or in combination if other agents are not known to cause HFSR.
  • Subjects must be 18 years or older.
  • Patients must provide written informed consent to participate in the study.
  • Women of childbearing potential and men must be willing to use an effective method of contraception while participating in this study and for at least two weeks after completing treatment in the study.
  • Women in this study need to have a negative urine pregnancy test before starting study medications.

Exclusion

  • Patients simultaneously taking another anti-cancer agent or combination of anti-cancer agents known to cause hand foot syndrome (pegylated doxorubicin, 5-fluorouracil, cytarabine).
  • Patients with an active dermatological condition due to previous chemotherapy or biologic therapy affecting the hands.
  • Patients with pre-existing dermatological condition affecting the hands or feet.
  • Women who have a positive pregnancy test or are lactating.

Key Trial Info

Start Date :

June 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2010

Estimated Enrollment :

6 Patients enrolled

Trial Details

Trial ID

NCT00667589

Start Date

June 1 2008

End Date

December 1 2010

Last Update

June 5 2013

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Northwestern University Feinberg School of Medicine, Department of Dermatology

Chicago, Illinois, United States, 60611